New drug combo shows promise in early breast cancer trial
NCT ID NCT01351909
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-phase trial tests a combination of two drugs, cyclophosphamide and veliparib, in people with HER2-negative breast cancer that has spread or cannot be surgically removed. The main goal is to find the safest dose and check for side effects. Up to 35 participants will receive the drugs to see if the combination can stop tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide and veliparib
- What this could lead to
- If successful, this could lead to a new combination therapy for HER2-negative metastatic breast cancer that may slow or stop tumor growth.
- What could go wrong
- This is an early Phase 1 trial with only 35 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2/NEU-NEGATIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Gene test could guide breast cancer treatment to boost survival
- Could a gentler chemo work for older breast cancer patients?
- Vaccine aims to block return of aggressive breast cancer
- Major trial pits three chemo drugs against each other for advanced breast cancer
- Genetic clues in blood and tumors could personalize breast cancer care